EverPoint Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

EverPoint Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.32M	Buy	+20,839	New	+$1.32M	0.02%	354

Other funds holding LGND

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EverPoint Asset Management's LGND Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in Ligand Pharmaceuticals (LGND) in Q4 2016: 20,839 shares worth $1.32M. The stake represents 0.02% of the portfolio and ranks #354 among its holdings.

269 funds tracked by Wall St. Rank hold LGND as of Q4 2016.

EverPoint Asset Management held 20,839 shares of Ligand Pharmaceuticals worth $1.32M as of Q4 2016.
Ligand Pharmaceuticals was a new EverPoint Asset Management position in Q4 2016.
Ligand Pharmaceuticals made up 0.02% of EverPoint Asset Management's portfolio in Q4 2016, its #354 holding.
269 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.